Key Takeaways
- • Permira sold Australia's largest radiology provider, I-Med Radiology Network, to Hong Kong-based Jardine Matheson for $2.4 billion USD, representing a near 39% return on the London PE firm's 2018 acquisition price of approximately $900 million.
- • I-Med operates 215 diagnostic imaging centers across Australia and New Zealand, processing ~7 million procedures annually, and has expanded into the U.S. market through its 2024 acquisition of StatRad, America's second-largest teleradiology provider at the time of purchase.
- • The transaction includes transfer of I-Med's minority stake in Australian artificial intelligence firm Harrison.ai, signaling continued focus on digital infrastructure and AI-driven radiology capabilities as core value drivers.
- • Jardine Matheson's acquisition of 100% ownership reflects a long-term commitment to regional healthcare consolidation, with stated plans for further expansion in core markets and new geographic territories under the conglomerate's ownership structure.
- • Permira's three-pillar growth strategy during its 2018–2026 ownership emphasized network expansion, AI transformation and digital infrastructure, and clinical excellence—demonstrating the operational value-creation thesis that justified the substantial exit multiple.
Summary
London-based private equity firm Permira has exited its ownership of I-Med Radiology Network, Australia's largest radiology provider, selling the business to Hong Kong-based multinational Jardine Matheson for $2.4 billion USD. The transaction closed in June 2026, delivering Permira a nearly 39% return on its $900 million acquisition of I-Med from fellow PE firm EQT in 2018. Lincoln Pan, CEO of Jardine Matheson, stated that the conglomerate views I-Med as a market leader poised for further expansion across existing and new markets.
I-Med's operational scale underscores the consolidation thesis within healthcare services. The network operates 215 diagnostic imaging centers across Australia and New Zealand, collectively processing approximately 7 million diagnostic procedures annually. The company has demonstrated geographic and service-line diversification through its 2024 acquisition of StatRad, which was America's second-largest teleradiology provider at the time of purchase, marking I-Med's entry into the U.S. market. The StatRad acquisition reflected strategic intent to build an integrated, multinational radiology platform.
The deal structure includes transfer of I-Med's minority stake in Harrison.ai, an Australian artificial intelligence firm, signaling continued emphasis on digital infrastructure and AI-enabled diagnostic capabilities. During Permira's ownership period, the PE firm articulated a three-pillar growth strategy: network expansion through bolt-on acquisitions, AI transformation and digital infrastructure modernization, and clinical excellence maintenance. This operational framework appears to have resonated with Jardine Matheson's acquisition thesis, positioning I-Med for further consolidation activity and geographic expansion under new ownership.
The transaction reflects broader trends in healthcare services PE investment, where radiology platforms—characterized by recurring revenue streams, clinical defensibility, and AI integration opportunities—remain attractive consolidation targets for both financial and strategic buyers.
I-Med's operational scale underscores the consolidation thesis within healthcare services. The network operates 215 diagnostic imaging centers across Australia and New Zealand, collectively processing approximately 7 million diagnostic procedures annually. The company has demonstrated geographic and service-line diversification through its 2024 acquisition of StatRad, which was America's second-largest teleradiology provider at the time of purchase, marking I-Med's entry into the U.S. market. The StatRad acquisition reflected strategic intent to build an integrated, multinational radiology platform.
The deal structure includes transfer of I-Med's minority stake in Harrison.ai, an Australian artificial intelligence firm, signaling continued emphasis on digital infrastructure and AI-enabled diagnostic capabilities. During Permira's ownership period, the PE firm articulated a three-pillar growth strategy: network expansion through bolt-on acquisitions, AI transformation and digital infrastructure modernization, and clinical excellence maintenance. This operational framework appears to have resonated with Jardine Matheson's acquisition thesis, positioning I-Med for further consolidation activity and geographic expansion under new ownership.
The transaction reflects broader trends in healthcare services PE investment, where radiology platforms—characterized by recurring revenue streams, clinical defensibility, and AI integration opportunities—remain attractive consolidation targets for both financial and strategic buyers.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.